|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 9 (May 1), 2000:
pp. 2786-2792
Autoimmune hemolytic anemia in chronic lymphocytic leukemia:
clinical, therapeutic, and prognostic features
Francesca R. Mauro,
Robert Foa,
Raffaella Cerretti,
Diana Giannarelli,
Serelina Coluzzi,
Franco Mandelli, and
Gabriella Girelli
Dipartimento di Biotecnologie Cellulari ed Ematologia and
Dipartimento di Medicina Sperimentale, University "La Sapienza,"
Rome, Italy.
Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed
within a series of 1203 patients (4.3%) with chronic lymphocytic leukemia (CLL) followed at a single institution. Nineteen were observed
at the time of CLL diagnosis and 33 during the clinical follow-up.
Ninety percent of the patients with CLL/AHA showed active CLL and 25%
had been treated previously. The antierythrocyte autoantibody (AeAb)
was an IgG in 87% of cases and an IgM in 13%. A lymphocyte count more
than 60 × 109/L (P < .00001), age above 65 years (P < .01), and male gender (P < .01)
emerged as independent parameters that correlated significantly with an
increased rate of AHA at CLL diagnosis. Patients previously treated
with chlorambucil (CB) plus prednisone (PDN) and with fludarabine plus
PDN showed a similar rate of AHA (1.8% and 2.5%, respectively). After
steroid therapy associated with CB in case of active CLL, 70% of
patients achieved the complete disappearance of the AeAb. The actuarial
AHA relapse-free survival probability was 54% at 5 years and the
median survival probability after AHA was 41 months. Infections
represented the main cause of morbidity and mortality. IgG AHA and the
occurrence of AHA at the same time of CLL diagnosis emerged as
independent factors significantly correlated with a better survival
probability of AHA/CLL patients. Taken together, this study indicates
that in CLL, AHA is a rare event with no independent effect on survival
for which steroids, associated with CB if required, and a careful
management of infections may successfully control the 2 conditions.
Cooperative studies are needed to better define the optimal steroid
schedule and the therapeutic role of other immunosuppressive agents and splenectomy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Dearden, R. Wade, M. Else, S. Richards, D. Milligan, T. Hamblin, D. Catovsky, and for the UK National Cancer Research Institute (NCR
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Blood,
February 15, 2008;
111(4):
1820 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Visco, M. Ruggeri, M. Laura Evangelista, R. Stasi, R. Zanotti, I. Giaretta, A. Ambrosetti, D. Madeo, G. Pizzolo, and F. Rodeghiero
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
Blood,
February 1, 2008;
111(3):
1110 - 1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt and N. E. Kay
Comprehensive Management of the CLL Patient: A Holistic Approach
Hematology,
January 1, 2007;
2007(1):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med,
September 19, 2006;
145(6):
435 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, E. A. Engels, N. E. Caporaso, G. Gridley, L. Mellemkjaer, K. Hemminki, M. S. Linet, and L. R. Goldin
Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries
Blood,
July 1, 2006;
108(1):
292 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2004;
2004(1):
163 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Guarini, G. Gaidano, F. R. Mauro, D. Capello, F. Mancini, M. S. De Propris, M. Mancini, E. Orsini, M. Gentile, M. Breccia, et al.
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features
Blood,
August 1, 2003;
102(3):
1035 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ruzickova, A. Pruss, M. Odendahl, K. Wolbart, G.-R. Burmester, J. Scholze, T. Dorner, and A. Hansen
Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in VH4-34 expressing single leukemic B cells
Blood,
October 16, 2002;
100(9):
3419 - 3422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. P. Hegde, W. H. Wilson, T. White, and B. D. Cheson
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia
Blood,
August 28, 2002;
100(6):
2260 - 2262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Iannitto, E. Ammatuna, C. Marino, S. Cirrincione, G. Greco, and G. Mariani
Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody
Blood,
February 1, 2002;
99(3):
1096 - 1097.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sallah, J. Y. Wan, and L. R. Hanrahan
Future Development of Lymphoproliferative Disorders in Patients with Autoimmune Hemolytic Anemia
Clin. Cancer Res.,
April 1, 2001;
7(4):
791 - 794.
[Abstract]
[Full Text]
|
|
|
| |
